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Introduction 26 
High salt1† intake is a major determinant of blood pressure (BP) in individuals and populations1. A 27 
reduction of salt intake leads to a reduction in BP and is associated with a reduction in the incidence 28 
of  cardiovascular disease (CVD)1-3. However, in the past few years, some epidemiological studies 29 
suggested the presence of a J-shaped association between salt (sodium) consumption and CVD4-8. 30 
These results sparked both scientific and media interest and opened a debate on the wisdom of 31 
pursuing population-wide salt reduction policies to reduce CVD, as currently recommended by 32 
most national and international health organizations, including the World Health Organization 33 
(WHO)9.  Systematic appraisal of these studies identified a variety of pitfalls, suggesting that their 34 
results were based on flawed methodologies, including the use of biased methods of assessing salt 35 
consumption10-11. The present scientific statement aims to briefly highlight the consequences of 36 
such biased estimates of exposure (salt intake) when assessing both individual salt intake (for 37 
associations with CVD) and population salt consumption (to evaluate population salt reduction 38 
programmes). 39 
 40 
Assessment of salt intake.  41 
The 24h urinary excretion of sodium is considered the reference method to assess salt consumption, 42 
since approximately 93% of the sodium ingested, mostly as salt†, is eliminated by the kidney in the 43 
next 24h12. If we ate the same amount of salt every day, a single 24h urine collection would indicate 44 
with a high degree of precision how much salt we eat. However, due to the high variability of salt 45 
consumption in an individual between days, many more collections on different days would be 46 
required to characterize the habitual individual’s salt consumption13. Therefore multiple 47 
assessments are needed, in prospective studies, to obtain a reliable estimate of the degree of 48 
association between habitual salt consumption and future risk of CVD 3,14-16. To overcome the high 49 
methodological burden of collecting complete 24h urine samples in large population-based studies 50 
                                                 
†Salt is sodium chloride – 2.5g of salt contain 1g of sodium.  
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in some settings, then, alternative easier methods have been proposed. Amongst those alternatives 51 
the use of ‘spot’ urine collections and the application of different formulae to derive 24h urinary 52 
sodium excretion have become of popular use4-8. The commonest is the Kawasaki17. This formula 53 
relies on urinary creatinine concentration from a spot collection and 24h urinary creatinine 54 
excretion predicted from age, sex, height and weight. It is, however, an inappropriate method for 55 
estimating salt intake in individuals, due to its unreliability and systematic bias18. These 56 
extrapolations consistently overestimate at lower levels of salt intake and underestimate at higher 57 
levels, introducing a systematic bias, detected in all validation studies performed to date, including 58 
the PURE Study11 (Figure 1). 59 
 60 
Consequences of estimating ‘individual’ sodium excretion in associations studies between salt 61 
intake and CVD. 62 
An accurate and unbiased measurement of ‘individual’ dietary sodium consumption is paramount 63 
in etiological epidemiology. In prospective studies, where multiple complete 24h urinary sodium 64 
collections have been used to measure exposure to salt consumption, consistent and graded 65 
relationships have been described between sodium excretion and health outcomes (CVD and all-66 
casue mortality) in general populations as well as in patients groups 3, 14-16. On the contrary, when 67 
studies have used the Kawasaki formula, a J-shaped relationship has been obtained4-8. Finally, 68 
when a  head-to-head comparison was carried out between measures of salt consumption obtained 69 
from repeated 24h urine collections compared to a spot urine, in the prospective assessment of salt 70 
and mortality, there was a graded relationship when salt consumption was assessed with multiple 71 
24h collections (with no evidence of increased risk at lower levels up to 3g of salt per day) whereas 72 
an ‘erroneous’ J-shaped curve was generated when using the Kawasaki formula from spot urines19. 73 
(Figure 2a) Therefore ‘spot’ urine collections with the use of the Kawasaki formula are an 74 
inappropriate method for studying associations in individuals in prospective studies, and should 75 
not be used in the context of prospective assessment of salt consumption as a predictor of health 76 
outcomes.  77 
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 78 
Consequences of estimating ‘population’ average salt consumption in the evaluation of salt 79 
reduction programmes. 80 
An accurate and unbiased measurement of ‘average’ dietary sodium consumption in population 81 
groups is paramount in public health and policy. The knowledge of a reliable estimate of population 82 
intake will help public health professionals in several ways. First, it will establish the size of the 83 
problem (how much salt does my population eat?). Second, it will provide the gap from set targets 84 
(how much do I have to reduce the average salt consumption to achieve WHO targets of 5g per 85 
day?). Third, it will help evaluate the intervention in populations by determining changes in 86 
average intake over time. Fourth, it will inform health economic evaluations of health impact and 87 
motivate continuous political commitment. So, the choice of the right method for measuring salt 88 
consumption is equally important in this setting. In a recent study in South Africa, the validity of 89 
different formulas – including Kawasaki -  applied to spot urine estimates of sodium were tested 90 
against 24h urinary sodium measurements. The study showed that these formulas all fall short of 91 
an ideal scenario when assessing the presence and size of the bias21. In the case of the Kawasaki 92 
formula the size of the bias was equivalent to 5.6g of salt21.  The important implication of these 93 
results for policy is that all these formulas introduce a bias with large inaccuracy both in the 94 
baseline estimation and, more importantly, they do not enable them to detect smaller changes in 95 
population salt consumption over time ensuing from salt reduction programmes. For instance, if 96 
spot urines with Kawasaki estimates had been applied to the evaluation of the 8-year UK national 97 
salt reduction programme, a detection of 1.4g per day reduction achieved over that period would 98 
not have been easy to detect given the presence of a bias three times as large. Therefore, the 99 
effectiveness of the population intervention would have been  missed, with crucial implications for 100 
further investments and commitments towards that public health policy. The real possibility of this 101 
scenario has been reported in the recent head-to-head comparison of an evaluation of the 102 
effectiveness of a 6-to-24 months salt-substitution programme in China within the framework of a 103 
well-controlled randomized clinical trial. Over the time of intervention there was a statistically 104 
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significant reduction in average sodium consumption of 0.35g per day (p=0.039) when assessed by 105 
24h urinary sodium excretion. However, when spot urines with Kawasaki equation were used, the 106 
change was detected as -0.09g per day (p=0.569), a quarter of the real effect (Figure 2b). Therefore 107 
‘spot’ urine collections with the use of the Kawasaki formula are an inappropriate method for 108 
studying population chages and should not be used in the context of a public health evaluation of 109 
the effectiveness of salt reduction programmes.  110 
 111 
Conclusions 112 
The evidence supporting global actions for a moderate reduction in salt consumption to prevent 113 
CVD is strong and new controversial studies, based on flawed methodology, are inappropriate to 114 
address the complex associations between salt intake and CVD outcomes and the evaluation of 115 
population salt reduction programmes. They should not overturn the ongoing concerted public 116 
health action to reduce salt intake globally.  117 
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Legends to figures 184 
 185 
Figure 1. Validation and comparison of the Kawasaki formula to estimate 24h urinary sodium excretion 186 
from a single morning spot urine sample in the PURE Study. On the left it is the validation in 1,083 187 
participants from 11 countries† and on the right it is the validation in 120 participants from the Shanxi 188 
Province of China#.  189 
 190 
† 1083 consecutive individuals attending follow-up clinics over a period of 2-6 months; 87 from India, 153 191 
from China and Colombia, 412 from Argentina, Brazil, Malaysia, South Africa, Turkey, 431 from Canada, 192 
Sweden, UAE. # 120 participants (60 rural and 60 urban) attending either 3-year or 6-year follow-up visit. 193 
Re-drawn from Mente A et al. J Hypertens 2014; 32: 1005-15 (left) and Peng Y et al. PLoS ONE 2016; 194 
11(2): e0149655 (right). 195 
 196 
Figure 2a. Errors in estimating usual sodium intake by the Kawasaki formula alter its relationship 197 
with mortality. Head-to-head comparison with 24h urinary sodium excretion. Re-drawn from He FJ et al. 198 
Int J Epidemiol 2018; 47: 1784-95. 199 
 200 
Figure 2b. Spot urine collections with Kawasaki equation is inadequate to monitor changes in population 201 
salt reduction programmes. Head-to-head comparison with 24h urinary sodium excretion. Drawn from 202 
Huang L et al. Int J Epidemiol 2018; 47: 1811-20 203 
 204 
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 206 
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Figure 1
Figure 2
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